Table 2 Perceived barriers to implementing intraprostatic focal boost in participants’ respective practices
Barrier | All participants (n = 258) (%) | Generalists (n = 68) (%) | Partial subspecialists (n = 119) (%) | Complete subspecialists (n = 70) (%) |
|---|---|---|---|---|
Concerns about registration accuracy between MRI and CT | 37 | 37 | 41 | 31 |
Concerns about risk of additional toxicity | 35 | 34 | 39 | 27 |
Challenges to accessing high-quality MRI | 29 | 32 | 34 | 19 |
Not aware or convinced of benefit | 24 | 25 | 25 | 21 |
Have not been trained to identify prostate tumors on MRI | 16 | 22 | 16 | 9 |
Dosimetrists need additional training to make high-quality plans | 16 | 21 | 13 | 16 |
Prefer brachytherapy boost | 14 | 9 | 13 | 20 |
Concerns about planning efficiency | 10 | 15 | 9 | 9 |
Other | 15 | 15 | 12 | 21 |